LONDON, March 11 (Reuters) – European and U.S. regulators are reviewing the safety of Gilead Sciences’ leukaemia drug Zydelig due to concerns over serious adverse events, including deaths.
The post UPDATE 1-Infection worries prompt regulatory reviews of Gilead leukaemia drug appeared first on NASDAQ.